CO2023004265A2 - Métodos para reducir el contenido de proteínas de la célula huésped en procesos de purificación de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteínas de la célula huésped - Google Patents

Métodos para reducir el contenido de proteínas de la célula huésped en procesos de purificación de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteínas de la célula huésped

Info

Publication number
CO2023004265A2
CO2023004265A2 CONC2023/0004265A CO2023004265A CO2023004265A2 CO 2023004265 A2 CO2023004265 A2 CO 2023004265A2 CO 2023004265 A CO2023004265 A CO 2023004265A CO 2023004265 A2 CO2023004265 A2 CO 2023004265A2
Authority
CO
Colombia
Prior art keywords
host cell
protein content
cell protein
methods
antibody
Prior art date
Application number
CONC2023/0004265A
Other languages
English (en)
Inventor
Brian David Bowes
Lara Ellen Krebs
Sarah M Richer
Lihua Huang
Steven A Plichta
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO2023004265A2 publication Critical patent/CO2023004265A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Water Supply & Treatment (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente descripción se refiere a métodos para reducir el contenido de proteínas de la célula huésped en una preparación de anticuerpo producido de forma recombinante en una célula huésped en el proceso de fabricación de anticuerpos destinados a la administración a un paciente. Los métodos descritos se pueden realizar para preparar preparaciones de anticuerpos terapéuticos que tengan proteínas de la célula huésped reducidas.
CONC2023/0004265A 2020-10-02 2023-03-31 Métodos para reducir el contenido de proteínas de la célula huésped en procesos de purificación de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteínas de la célula huésped CO2023004265A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063086915P 2020-10-02 2020-10-02
PCT/US2021/053407 WO2022072934A1 (en) 2020-10-02 2021-10-04 Methods for reducing host cell protein content in antibody purification processes and antibody compositions having reduced host cell protein content

Publications (1)

Publication Number Publication Date
CO2023004265A2 true CO2023004265A2 (es) 2023-04-27

Family

ID=78621988

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0004265A CO2023004265A2 (es) 2020-10-02 2023-03-31 Métodos para reducir el contenido de proteínas de la célula huésped en procesos de purificación de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteínas de la célula huésped

Country Status (17)

Country Link
US (2) US20230374063A1 (es)
EP (2) EP4222159A1 (es)
JP (2) JP2023545019A (es)
KR (2) KR20230061462A (es)
CN (2) CN116547292A (es)
AR (1) AR123688A1 (es)
AU (2) AU2021355521A1 (es)
BR (1) BR112023004871A2 (es)
CA (2) CA3193722A1 (es)
CL (1) CL2023000961A1 (es)
CO (1) CO2023004265A2 (es)
EC (1) ECSP23024034A (es)
IL (2) IL301584A (es)
MX (2) MX2023003863A (es)
PE (1) PE20231507A1 (es)
TW (1) TW202229307A (es)
WO (2) WO2022072919A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024068996A1 (en) 2022-09-30 2024-04-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201702922VA (en) * 2008-10-20 2017-06-29 Abbvie Inc Isolation and purification of antibodies using protein a affinity chromatography
ME02352B (me) 2010-08-12 2016-06-20 Lilly Co Eli PROTUTIJELA PROTIV N3pGiu-AMILOlDNOG BETA PEPTlDA l NJIHOVA UPOTREBA
WO2012136552A1 (en) * 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
WO2015175769A1 (en) * 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
WO2018170488A1 (en) * 2017-03-17 2018-09-20 Gilead Sciences, Inc. Method of purifying an antibody
JOP20190247A1 (ar) 2017-04-20 2019-10-20 Lilly Co Eli أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
PE20221893A1 (es) * 2020-04-02 2022-12-13 Regeneron Pharma Anticuerpos contra glicoproteina de espicula anti-sars-cov-2 y fragmentos de union al antigeno

Also Published As

Publication number Publication date
EP4222159A1 (en) 2023-08-09
CL2023000961A1 (es) 2023-11-03
WO2022072934A1 (en) 2022-04-07
JP2023545019A (ja) 2023-10-26
BR112023004871A2 (pt) 2023-04-25
ECSP23024034A (es) 2023-04-28
CN116348486A (zh) 2023-06-27
AU2021355521A1 (en) 2023-05-11
AU2021355518A1 (en) 2023-06-08
CA3193722A1 (en) 2022-04-07
MX2023003863A (es) 2023-04-14
US20230406914A1 (en) 2023-12-21
AU2021355518A9 (en) 2024-02-08
KR20230061462A (ko) 2023-05-08
PE20231507A1 (es) 2023-09-26
AR123688A1 (es) 2023-01-04
MX2023003836A (es) 2023-04-14
EP4222160A1 (en) 2023-08-09
CN116547292A (zh) 2023-08-04
KR20230078748A (ko) 2023-06-02
US20230374063A1 (en) 2023-11-23
JP2023544399A (ja) 2023-10-23
CA3192910A1 (en) 2022-04-07
IL301572A (en) 2023-05-01
IL301584A (en) 2023-05-01
TW202229307A (zh) 2022-08-01
WO2022072919A1 (en) 2022-04-07

Similar Documents

Publication Publication Date Title
Lacroix et al. Isolation and characterization of peptides with dipeptidyl peptidase-IV inhibitory activity from pepsin-treated bovine whey proteins
Czarnetzki Urticaria
CO2023004265A2 (es) Métodos para reducir el contenido de proteínas de la célula huésped en procesos de purificación de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteínas de la célula huésped
EA201790989A1 (ru) Стабильный препарат раствора белка, содержащего анти-vegf антитело в высокой концентрации
BR112013019975A2 (pt) proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
PH12019500440A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
AR092532A1 (es) Etanercept correctamente plegado de alta pureza y excelente rendimiento
BR112013020338A2 (pt) proteína de ligação de antígeno monovalente, composição farmacêutica, uso da proteína de ligação de antígeno monovalente, método para o tratamento de um paciente com necessidade de terapia, método para a preparação de uma proteína de ligação de antígeno monovalente, ácido nucleico, vetor e célula hospedeira
BRPI0814097A8 (pt) Derivado do peptídeo insulinotrópico cm seu aminoácido n-terminal modificado
HRP20050934B1 (hr) Formulacije s visokom koncentracijom antitijela i proteina
BR112016003358A2 (pt) método para aumentar a expressão de proteínas codificadas por rna
BRPI0713421A2 (pt) Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
CR8932A (es) Composicion de anticuerpo her2
CL2013003248A1 (es) Composición inmunogenica que comprende una glucoproteina g de los virus hendra y nipah y un complejo inmunoestimulante; método para producir una respuesta de anticuerpo neutralizante contra un virus hendra y/o nipah en un sujeto.
AR082257A1 (es) Composicion de inmunoglobulinas humanas concentradas, procedimiento
BR112015032572A2 (pt) composições e métodos para melhorar o desempenho durante exercícios
AR093908A1 (es) Fusion de la hormona de crecimiento humana y albumina, formulacion y usos de la misma
FI3672631T3 (fi) Beeta-amyloidin vasta-aineita sisältäviä lääkekoostumuksia
AR093365A1 (es) Formulacion para polipeptidos
CL2023002602A1 (es) Uso de células madre mesenquimales sobreexpresoras de pacer para el tratamiento de enfermedades con origen y/o componente inflamatorio
BR112012026999A2 (pt) peptídeo de caseína para uso no tratamento de infecções uterinas.
BR112023017887A2 (pt) Proteína compreendendo um primeiro polipeptídeo e um segundo polipeptídeo, anticorpo biespecífico, ácido nucleico de codificação do dito primeiro ou segundo polipeptídeo, célula hospedeira, composição farmacêutica, proteína, anticorpo biespecífico ou composição farmacêutica para uso, e, métodos de tratamento e de preparo de um anticorpo biespecífico
WO2023027899A3 (en) Compositions and methods of mrna therapeutics
BR112023005795A2 (pt) Proteína de fusão recombinante, molécula de ácido nucleico, vetor de expressão, célula, composição, composição farmacêutica, kit, método para tratar uma doença imune e método para tratar câncer
EA201791319A1 (ru) Композиция хлорофиллов